Endo Health Solutions Inc (NASDAQ:ENDP) updated its FY14 earnings guidance on Friday. The company provided EPS guidance of $3.40-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.93, American Banking & Market News reports. The company issued revenue guidance of $2.50-2.62 billion, compared to the consensus revenue estimate of $2.56 billion. Endo Health Solutions Inc (NASDAQ:ENDP) stock opened at $80.00 in last session, and closed at $79.82, while the day range of ENDP stock is $75.86-$80.15.The stock showed a positive weekly performance of 1.75%.
Medivation Inc. (NASDAQ:MDVN) has issued its fourth quarter and full year results for the period ending December 31, 2013 in which earnings per share for the quarter beat consensus estimates. The year was extremely productive as XTANDI performed extremely well in mCRPC patients chemotherapy accompanied by positive results from phase 3 PREVAIL study as well as enrollment of ongoing clinical studies in pre-chemotherapy patients. Medivation Inc. (NASDAQ:MDVN) stock opened at $73.53, in last session and closed at $71.91, by loosed -14.92%.The 52 week range was $41.89-$88.20.Company’s market capitalization is $5.43 billion.
Enzymotec Ltd. (NASDAQ:ENZY) announced the pricing of a registered secondary public offering. The size of the offering has been increased to 4,698,857 ordinary shares at a price of $28.00 per share. The underwriters have a 30-day option to purchase up to an additional 704,828 ordinary shares at the public offering price. All of the shares are being sold by the Company’s shareholders. The Company will not receive any proceeds from the sale of these shares. The offering is expected to close on March 5, 2014, subject to customary closing conditions. Enzymotec Ltd. (NASDAQ:ENZY) stock loosed -4.62% and finished the last session at $27.90.The EPS of the stock remained 1.04.Company’s market capitalization is $88.37 million.
Vermillion, Inc. (NASDAQ:VRML), a multivariate diagnostics company focused on gynecologic cancers and women’s health, will hold a conference call on Thursday, March 6, 2014, at 4:30 p.m. Eastern time to discuss results for the fourth quarter and year ended December 31, 2013. Financial results will be issued in a press release prior to the call. Vermillion’s President and CEO Thomas McLain will host the call, followed by a question and answer period. Date: Thursday, March 6, 2014 Time: 4:30 p.m. Eastern time (3:30 p.m. Central time). Vermillion, Inc. (NASDAQ:VRML) stock opened the session at $3.25, and closed the session at $3.40. The 52 week range of the VRML stock remained $1.03-$4.07 and the day range was $3.18-$3.50.